SignalHF vs Viz HCM
AI Verdict
Choose SignalHF if…
Choose SignalHF if your primary objective is to proactively prevent heart failure hospitalizations in patients already equipped with various cardiac implantable electronic devices (CIEDs). This tool is ideal for care teams seeking to leverage manufacturer-agnostic AI analysis of CIED data to identify high-risk patients and enable early, personalized interventions to improve outcomes.
View SignalHF →Choose Viz HCM if…
Choose Viz HCM if your institution aims to significantly accelerate the detection and streamline the care pathway for patients with suspected Hypertrophic Cardiomyopathy (HCM). This solution is best suited for environments needing real-time AI analysis of ECGs to rapidly identify HCM and efficiently coordinate multidisciplinary care teams, reducing time to diagnosis and treatment.
View Viz HCM →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz HCMViz HCM emphasizes mobile-based alerts and seamless integration with existing EHR and PACS systems, offering a comprehensive patient view and real-time access to echo images and reports via a mobile app. This focus on immediate, integrated, and mobile access for multidisciplinary teams suggests a highly actionable and user-friendly experience within clinical workflows.
Clinical Value
Viz HCMWhile both are FDA-cleared and offer significant clinical benefits, Viz HCM has a more extensive and publicly documented body of clinical validation, including multiple real-world studies and publications demonstrating its effectiveness in detecting HCM and reducing diagnosis time. SignalHF also has clinical validation through the FORESEE-HF study, but Viz HCM's breadth of evidence appears greater.
Pricing & Value
Viz HCMViz HCM offers greater transparency regarding its pricing model, explicitly stating it is subscription-based and providing details on CMS reimbursement with specific CPT codes and payment rates effective January 1, 2025. This level of detail allows healthcare systems to better assess the financial value and potential return on investment, whereas SignalHF only states 'Contact for pricing'.
Enterprise Readiness
Viz HCMBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, indicating a strong foundation for enterprise use. However, Viz HCM explicitly details its extensive integration capabilities with EHR and PACS systems, and its 'Viz.ai One' platform is designed for enterprise-wide care coordination across various specialties, with adoption in over 1,700 hospitals. SignalHF also mentions EHR integration, but Viz HCM's documented integration ecosystem appears more robust and widely implemented.
Innovation
TieBoth tools demonstrate significant innovation in cardiac care. SignalHF offers manufacturer-agnostic predictive AI for heart failure hospitalizations using data from various CIEDs, including pacemakers, which is a notable advancement. Viz HCM's real-time AI-powered ECG analysis for HCM detection received De Novo FDA approval, establishing a new regulatory category for cardiovascular machine learning-based notification software, highlighting its pioneering nature.
Support & Docs
Viz HCMViz HCM provides more explicit and comprehensive details about its support infrastructure, including a dedicated 'Support Center,' 'Help Center,' 'Customer Resources,' 'User Guides,' and 'Viz Academy.' They also offer 24/7/365 urgent phone support and email support. While SignalHF mentions a 'Customer Success team' and responsive support, Viz HCM's documented offerings appear more extensive and readily available.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | SignalHF | Viz HCM |
|---|---|---|
| Primary Function | Predicts heart failure hospitalizations within 30 days. | Detects suspected Hypertrophic Cardiomyopathy (HCM) using real-time ECG analysis. |
| Target Condition | Heart Failure | Hypertrophic Cardiomyopathy (HCM) |
| Data Analyzed | Data from various cardiac implantable electronic devices (CIEDs), physiological data, demographics, lead measurements, episodes, and therapies. | Real-time ECG analysis. |
| Alert Mechanism | Generates automatic alerts for care teams based on risk scores; AI-driven alert management to filter and highlight relevant events. | Mobile-based alerts and notifications to multidisciplinary care teams. |
| Compatibility/Integration | Manufacturer-agnostic compatibility with various CIEDs (pacemakers, ICDs, CRTs); Unified platform for centralizing cardiac implantable device data. | Seamless integration with existing clinical workflows, EHR, and PACS systems. |
Videos
Demos, reviews, and walkthroughs featuring SignalHF and Viz HCM.